Related Experiment Video
Updated: Jun 22, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long-Established Target Mitochondrial Pyruvate Carrier
Abstract:
Targeting NLRP3 inflammasome has been recognized as a promising therapeutic strategy for the treatment of numerous common diseases. UK5099, a long-established inhibitor of mitochondrial pyruvate carrier (MPC), is previously found to inhibit macrophage inflammatory responses independent of MPC expression. However, the mechanisms by which UK5099 inhibit inflammatory responses remain unclear. Here, it is shown that UK5099 is a potent inhibitor of the NLRP3 inflammasome in both mouse and human primary macrophages. UK5099 selectively suppresses the activation of the NLRP3 but not the NLRC4 or AIM2 inflammasomes. Of note, UK5099 retains activities on NLRP3 in macrophages devoid of MPC expression, indicating this inhibitory effect is MPC-independent. Mechanistically, UK5099 abrogates mitochondria-NLRP3 interaction and in turn inhibits the assembly of the NLRP3 inflammasome. Further, a single dose of UK5099 persistently reduces IL-1β production in an endotoxemia mouse model. Importantly, structure modification reveals that the inhibitory activities of UK5099 on NLRP3 are unrelated to the existence of the activated double bond within the UK5099 molecule. Thus, this study uncovers a previously unknown molecular target for UK5099, which not only offers a new candidate for the treatment of NLRP3-driven diseases but also confounds its use as an MPC inhibitor in immunometabolism studies.
Insights
UK5099, an inhibitor of mitochondrial pyruvate carrier (MPC), potently inhibits the NLRP3 inflammasome, independent of MPC. This discovery offers new therapeutic avenues for NLRP3-driven diseases and impacts immunometabolism research.
Area of Science:
- Immunology
- Molecular Biology
- Drug Discovery
Background:
- The NLRP3 inflammasome is a key target for treating inflammatory diseases.
- UK5099, an established mitochondrial pyruvate carrier (MPC) inhibitor, has shown anti-inflammatory effects independent of MPC.
- The precise mechanisms of UK5099's anti-inflammatory action were previously unclear.
Purpose of the Study:
- To investigate the molecular mechanisms underlying UK5099's anti-inflammatory effects.
- To determine if UK5099 targets the NLRP3 inflammasome.
- To explore the therapeutic potential of UK5099 in NLRP3-mediated inflammatory conditions.
Main Methods:
- Assessed UK5099's effect on NLRP3 inflammasome activation in mouse and human macrophages.
- Utilized macrophages lacking MPC expression to confirm MPC-independent activity.
- Investigated the interaction between mitochondria and NLRP3 upon UK5099 treatment.
- Evaluated the in vivo efficacy of UK5099 in an endotoxemia mouse model.
- Performed structure-activity relationship studies on UK5099.
Main Results:
- UK5099 demonstrated potent and selective inhibition of NLRP3 inflammasome activation, without affecting NLRC4 or AIM2.
- The inhibitory effect of UK5099 on NLRP3 was confirmed to be independent of MPC expression.
- UK5099 was found to disrupt the interaction between mitochondria and NLRP3, preventing inflammasome assembly.
- A single dose of UK5099 significantly reduced IL-1β production in vivo.
- Structural analysis indicated that the inhibitory activity of UK5099 is not dependent on its activated double bond.
Conclusions:
- UK5099 is a novel and potent inhibitor of the NLRP3 inflammasome, acting via disruption of mitochondria-NLRP3 interaction.
- This finding identifies UK5099 as a potential therapeutic agent for NLRP3-driven inflammatory diseases.
- The MPC-independent NLRP3 inhibitory activity of UK5099 necessitates re-evaluation of its use in immunometabolism studies.
More Related Videos
Related Concept Videos
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Protein Transport into the Inner Mitochondrial Membrane
Transport of mitochondrial precursors across the TIM23 channel is driven by...
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Pyruvate Oxidation
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Mitochondrial Protein Sorting
Most of these mitochondrial proteins are encoded by the nucleus and imported to the mitochondria as unfolded or loosely folded precursors. Mitochondrial precursors...

